-
15:00
Understanding the radiation risks associated with molecular imaging
-
Michael K. O'Connor
(Mayo Clinic, Section of Nuclear Medicine, Rochester)
-
15:20
Role of 2-[18F]FDG as a Radiopharmaceutical for PET/CT in patients with COVID-19
-
Arturo Chiti
(Humanitas University – Milan – Italy)
-
15:40
What molecular imaging of cancer patients can teach us about COVID-19
-
Silvana Del Vecchio
(Nuclear Medicine, Department of Advanced Biomedical Sciences, University Federico II)
-
16:15
18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?
-
E. Guedj
(Nuclear Medicine, Univ. Marseille)
-
16:35
The role for dynamic imaging
-
Irène Buvat
(Curie Institute – Orsay)